Whitehawk Therapeutics (WHWK) Cash from Financing Activities (2010 - 2026)
Whitehawk Therapeutics (WHWK) posted quarterly Cash from Financing Activities of $25000.0 for Q4 2025, down 52.83% year-over-year from $53000.0 in Q4 2024, and up 102.94% quarter-over-quarter from -$850000.0 in Q2 2025.
Whitehawk Therapeutics (WHWK) Cash from Financing Activities (2010 - 2026) Analysis & Trends
Whitehawk Therapeutics (WHWK) has reported Cash from Financing Activities for 12 consecutive years, with $25000.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Cash from Financing Activities fell 52.83% year-over-year to $25000.0; the TTM figure through Mar 2026 stood at -$825000.0 (down 100.87% YoY), while the FY2025 annual figure was $94.4 million, up 72496.92% from the prior year.
- Cash from Financing Activities improved to $25000.0 in Q4 2025 per WHWK's latest filing, from -$850000.0 in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $141.7 million in Q3 2021 and bottomed at -$850000.0 in Q2 2025.
- Historically, Cash from Financing Activities has averaged $17.2 million across 5 years, with a median of $61639.5 in 2021.
- On a YoY basis, Cash from Financing Activities climbed as much as 952110.0% in 2025 and fell as far as 1077.01% in 2025.
- Whitehawk Therapeutics' Cash from Financing Activities stood at $88000.0 in 2021, then tumbled by 221.59% to -$107000.0 in 2022, then surged by 174.77% to $80000.0 in 2023, then slumped by 33.75% to $53000.0 in 2024, then tumbled by 52.83% to $25000.0 in 2025.
- Business Quant data shows WHWK's Cash from Financing Activities at $25000.0 in Q4 2025, -$850000.0 in Q2 2025, and $95.2 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.42 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -6.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -207,909.22 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -273.15 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 36.24 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 27.18 Mn |
| 10 | Whitehawk Therapeutics | 369.67 Mn | 74.92 Mn | - | 81.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 81.84 Mn |
| Jun 30, 2026 | 81.84 Mn |
| Dec 31, 2025 | 25,000.00 |
| Dec 31, 2025 | 25,000.00 |
| Jun 30, 2025 | -850,000.00 |
| Jun 30, 2025 | -850,000.00 |
| Mar 31, 2025 | 95.20 Mn |
| Mar 31, 2025 | 95.20 Mn |
| Dec 31, 2024 | 53,000.00 |
| Dec 31, 2024 | 53,000.00 |
| Jun 30, 2024 | 87,000.00 |
| Jun 30, 2024 | 87,000.00 |
| Mar 31, 2024 | -10,000.00 |
| Mar 31, 2024 | -10,000.00 |
| Dec 31, 2023 | 80,000.00 |
| Dec 31, 2023 | 80,000.00 |
| Sep 30, 2023 | -75,000.00 |
| Sep 30, 2023 | -75,000.00 |
| Jun 30, 2023 | 313,000.00 |
| Jun 30, 2023 | 313,000.00 |